Antidepressants and seizures: Emphasis on newer agents and clinical implications

International Journal of Clinical Practice

Volumn 59, Issue 12, 2005, Pages 1435-1440

  Montgomery, Stuart A ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Antidepressants; Clinical implications; Overdose; Predisposition; Seizure

Indexed keywords

AMFEBUTAMONE; AMOXAPINE; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DOSULEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LITHIUM; MAPROTILINE; MILNACIPRAN; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; PAROXETINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TETRACYCLIC ANTIDEPRESSANT AGENT; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; ADRENERGIC RECEPTOR AFFECTING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOPAMINE UPTAKE INHIBITOR;

BODY WEIGHT DISORDER; CLINICAL TRIAL; DEPRESSION; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG CLASSIFICATION; DRUG OVERDOSE; DRUG TOLERABILITY; HUMAN; NONHUMAN; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEDATION; SEIZURE; SEIZURE THRESHOLD; SEXUAL DYSFUNCTION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; WEIGHT GAIN; CHEMICALLY INDUCED DISORDER; MAJOR DEPRESSION;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC UPTAKE INHIBITORS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER, MAJOR; DOPAMINE UPTAKE INHIBITORS; HUMANS; MONOAMINE OXIDASE INHIBITORS; SEIZURES; SEROTONIN UPTAKE INHIBITORS;

EID: 33646844086     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2005.00731.x     Document Type: Review

References (46)

1. Pubmed, National Library of Medicine, National Institute of Health, US Department of Health and Human Services. http://www.ncbi.nlm.nih.gov/entrez
2. Dailey JW, Naritoku DK. Antidepressants and seizure: Clinical anecdotes overshadow neuroscience. Biochem Pharmacol 1996; 52: 1323-9.
3. Forsgren L, Beghi E, Oun A, Sillanpaa M. The epidemiology of epilepsy in Europe -a systematic review. Eur J Neurol 2005; 12: 245-53.
4. Leber P. Adverse drug reactions - "time-less"risks (a hazard of risk assessment: The example of seizure and antidepressants). Psychopharmacol Bull 1985; 21: 334-8.
5. Rosenstein DL, Nelson JC, Jacobs SC. Seizures associated with antidepressants: A review. J Clin Psychiatry 1993; 54: 289-99.
6. Baldessarini RJ. Drugs and the treatment of psychiatric disorder. In: Gilma AG, Goodman LS, Gilman A, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 6th edn. New York: McMillan, 1980: 418-30.
7. Trimble M. Non-monoamine oxidase inhibitor antidepressants and epilepsy: a review. Epilepsia 1978; 19: 241-50.
8. Edwards JG. Antidepressants and convulsions. Lancet 1979; 2: 1368-9.
9. Pisani F, Oteri G, Costa C, Di Raimondo G, Di Perri R. Effects of psychotropic drugs on seizure threshold. Drug Saf 2002; 25: 91-110.
10. Lee KC, Finley PR, Alldredge BK. Risk of seizures associated with psychotropic medications: Emphasis on new drugs and new findings. Expert Opin Drug Saf 2003; 2: 233-47.
11. Peck AW, Stern WC, Watkinson C. Incidence of seizures during treatment with tricyclic antidepressant drugs and bupropion. J Clin Psychiatry 1983; 44 (Sec 2): 197-201.
12. Lowry MR, Dunner FJ. Seizures during tricyclic therapy. Am J Psychiatry 1980; 137: 1461-2.
13. Jick H, Dinan BJ, Hunter JR et al. Tricyclic antidepressants and convulsions. J Clin Psychopharmacol 1983; 3: 182-5.
14. Blair D. Treatment of severe depression by imipramine (Tofranil): An investigation of 100 cases. J Ment Sci 1960; 106: 891-905.
15. Kiloh LG, Davison K, Osselton JW. An electroencephalographic study on the analeptic effects of imipramine. Electroencephalogr Clin Neurophysiol 1961; 13: 216-23.
16. Leyberg JT, Denmark JC. The treatment of depressive states with imipramine hydrochloride (Tofranil). J Ment Sci 1959; 105: 1123-6.
17. Tonne BK, Fenton GW. Epileptic seizures induced by psychotropic drugs. Psychol Med 1977; 7: 265-70.
18. Gelzer J. Limits to chemotherapy of depression. Psychopathology 1986; 19 (Suppl. 2): 108 -17.
19. Jick SS, Jick H, Knauss TA, Dean AD. Antidepressants and convulsions. J Clin Psychopharmacol 1992; 12: 241-5.
20. Physicians' Desk Reference, 52nd edn. Montvale: Thompson PDR, 1998.
21. Skowron DM, Stimmel GL. Antidepressants and the risk of seizures. Pharmacotherapy 1992; 12: 18-22.
22. Jabbari B, Bryan GE, March EE, Gunderson CH. Incidence of seizures with tricyclic and tetracyclic antidepressants. Arch Neurol 1985; 42: 480-1.
23. Dessain EC, Schatzberg AF, Woods BT, Cole JO. Maprotiline treatment in depression. Arch Gen Psychiatry 1966; 43: 86-90.
24. Schaul N, DeGreef G, Ney G. Psychotropic drugs and seizures. In: Kane JM, Lieberman JA, eds. Adverse Effects of Psychotropic Drugs. New York: Guilford Press, 1992: 324-37.
25. Bisserbe JC, Lepine JP. Moclobemide in social phobia: A pilot open study. Clin Neuropharmacol 1994; 17 (Suppl. 1): S88-S94.
26. Boshier A, Wilton LV, Shakir SAW. Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000. Eur J Clin Pharmacol 2003; 59: 767-73.
27. Edwards JG, Inman WHW, Wilton L, Pearce GL. Prescription-event monitoring of 10,401 patients treated with fluvoxamine. Br J Psychiatry 1994; 164: 387-95.
28. Shakir S. Prescription-Event Monitoring. In: Mann RD, Andrews E, eds. Pharmacovigilance: John Wiley and Sons Ltd UK, 2002: 333-44.
29. Physicians' Desk Reference, 58th edn. Montvale: Thompson PDR, 2004.
30. Cymbalta, EuropeanPublicAssessmentReport, Scientific Discussion. http://www.emea.eu.int/humandocs/humans/EPAR/cymbalta/cymbalta.htm
31. Leinonen E, Lepola U, Koponen H, Mehtonen OP, Rimon R. Long-term efficacy and safety of milnacipran compared to clomipramine in patients with major depression. Acta Psychiatr Scand 1997; 96: 497-504.
32. Stahl SM. Essential Psychopharmacology, Neuroscientific Basis and Practical Applications, 2nd edn. Cambridge: Cambridge University Press, 2000: 199-295.
33. Dunner DL, Zisook S, Billow AA, Batey SR, Johnston JA, Ascher JA. A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J Clin Psychiatry 1998; 59: 366-73.
34. Johnston JA, Lineberry CG, Ascher JA et al. A 102-center prospective study of seizure in association with bupropion. J Clin Psychiatry 1991; 52: 450-6.
35. Mirtazapine: Seizures and neutropenia. Prescrire Int 2004; 13: 58.
36. Thanacoody HKR, Thomas SHL. Antidepressant poisoning. Clin Med 2003; 3: 114-8.
37. Whyte IM, Dawson AH, Buckley NA. Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. QJM 2003; 96: 369-74.
38. Alldredge BK. Seizure risk associated with psychotropic drugs: Clinical and pharmacokinetic considerations. Neurology 1999; 53 (Suppl. 2): S68-S75.
39. Isbister GK, Hackett LP, Dawson AH, Whyte IM, Smith AJ. Moclobemide poisoning: Toxicokinetics and occurrence of serotonin toxicity. Br J Clin Pharmacol 2003; 56: 441-50.
40. Cuenca PJ, Holt KR, Hoefle JD. Seizure secondary to citalopram overdose. J Emerg Med 2004; 26: 177-81.
41. Kelly CA, Dhaun N, Laing WJ, Strachan FE, Good AM, Bateman DN. Comparative toxicity of citalopram and newer antidepressants after overdose. J Toxicol Clin Toxicol 2004; 42: 67-71.
42. Buckley NA, Faunce TA. 'Atypical' antidepressants in overdose, clinical considerations with respect to safety. Drug Saf 2003; 26: 539-51.
43. Pisani F, Spina E, Oteri G. Antidepressant drugs and seizure susceptibility: From in vitro data to clinical practice. Epilepsia 1999; 40 (Suppl. 10): S48-S56.
44. Delanty N, Vaughan CJ, French JA. Medical causes of seizures. Lancet 1998; 352: 383-90.
45. Flores G, Perez-Patrigeon S, Cobos-Ayala C, Vergara J. Severe symptomatic hyponatremia during citalopram therapy -a case report. BMC Nephrol 2004; 5: 2.
46. Spigset O, Hedenmaim K, Dahl ML., Seizures and myoclonus associated with antidepressant treatment: Assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms and treatment with CYP2D6 inhibitrors. Acta Psychiatr Scand 1997; 96: 379-84.